223 related articles for article (PubMed ID: 12942124)
1. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.
Vernimmen D; Gueders M; Pisvin S; Delvenne P; Winkler R
Br J Cancer; 2003 Sep; 89(5):899-906. PubMed ID: 12942124
[TBL] [Abstract][Full Text] [Related]
2. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
Savinainen KJ; Saramäki OR; Linja MJ; Bratt O; Tammela TL; Isola JJ; Visakorpi T
Am J Pathol; 2002 Jan; 160(1):339-45. PubMed ID: 11786427
[TBL] [Abstract][Full Text] [Related]
3. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
Delacroix L; Begon D; Chatel G; Jackers P; Winkler R
DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159
[TBL] [Abstract][Full Text] [Related]
4. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen.
Perissi V; Menini N; Cottone E; Capello D; Sacco M; Montaldo F; De Bortoli M
Oncogene; 2000 Jan; 19(2):280-8. PubMed ID: 10645007
[TBL] [Abstract][Full Text] [Related]
5. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
6. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.
Begon DY; Delacroix L; Vernimmen D; Jackers P; Winkler R
J Biol Chem; 2005 Jul; 280(26):24428-34. PubMed ID: 15870067
[TBL] [Abstract][Full Text] [Related]
7. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.
Allouche A; Nolens G; Tancredi A; Delacroix L; Mardaga J; Fridman V; Winkler R; Boniver J; Delvenne P; Begon DY
Breast Cancer Res; 2008; 10(1):R9. PubMed ID: 18218085
[TBL] [Abstract][Full Text] [Related]
8. Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.
Nolens G; Pignon JC; Koopmansch B; Elmoualij B; Zorzi W; De Pauw E; Winkler R
Breast Cancer Res; 2009; 11(6):R83. PubMed ID: 19906305
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of p185 is not related to erbB2 amplification in ovarian cancer.
Morali F; Cattabeni M; Tagliabue E; Campiglio M; Menard S; Marzola M; Lucchini V; Colombo N; Mangioni C; Redaelli L
Ann Oncol; 1993 Nov; 4(9):775-9. PubMed ID: 7904177
[TBL] [Abstract][Full Text] [Related]
10. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression.
Vernimmen D; Begon D; Salvador C; Gofflot S; Grooteclaes M; Winkler R
Biochem J; 2003 Feb; 370(Pt 1):323-9. PubMed ID: 12418962
[TBL] [Abstract][Full Text] [Related]
11. ErbB2 activation of ESX gene expression.
Neve RM; Ylstra B; Chang CH; Albertson DG; Benz CC
Oncogene; 2002 May; 21(24):3934-8. PubMed ID: 12032832
[TBL] [Abstract][Full Text] [Related]
12. Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.
Benz CC; Fedele V; Xu F; Ylstra B; Ginzinger D; Yu M; Moore D; Hall RK; Wolff DJ; Disis ML; Eppenberger-Castori S; Eppenberger U; Schittulli F; Tommasi S; Paradiso A; Scott GK; Albertson DG
Genes Chromosomes Cancer; 2006 Nov; 45(11):983-94. PubMed ID: 16883574
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
14. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J
Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186
[TBL] [Abstract][Full Text] [Related]
15. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
16. [Amplification and overexpression of c-erbB2 in human breast cancer].
Chen Y; Dong J; Li C
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
[TBL] [Abstract][Full Text] [Related]
17. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
18. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis.
Beckers J; Herrmann F; Rieger S; Drobyshev AL; Horsch M; Hrabé de Angelis M; Seliger B
Int J Cancer; 2005 Apr; 114(4):590-7. PubMed ID: 15609325
[TBL] [Abstract][Full Text] [Related]
20. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
Savinainen KJ; Linja MJ; Saramäki OR; Tammela TL; Chang GT; Brinkmann AO; Visakorpi T
Br J Cancer; 2004 Mar; 90(5):1041-6. PubMed ID: 14997205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
